Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer Eiko Theodora Browning, MD, Andrew James.

MET-Mutated NSCLC with Major Response to Crizotinib

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib Naoki Omachi, MD, Shigeki.

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK Satoshi Anai, MD, Masafumi.

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Operation and Chemotherapy: Prognostic Factors for Lung Cancer With One Synchronous Metastasis Anne-Claire Toffart, MD, PhD, Michaël Duruisseaux, MD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Dramatic Response to Pemetrexed in a Patient with Pneumonic-Type Mucinous Bronchioloalveolar Carcinoma David H. Garfield, MD, Wilbur Franklin, MD Journal.

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged.

Aya Fukuizumi, MD Journal of Thoracic Oncology

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable.

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD

Collaterals Journal of Thoracic Oncology

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

David Garfield, MD Journal of Thoracic Oncology

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu, MD, Anne-Claire Toffart, MD, Denis Moro-Sibilot, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 8, Pages e1-e2 (August 2012) DOI: 10.1097/JTO.0b013e318257fc1d Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Chest CT scan howing lung disease in remission after treatment by crizotinib. B, Abdominal CT scan at the finish of crizotinib treatment without any liver lesion (a normal CT scan—January 12, 2011). CT, computed tomography. Journal of Thoracic Oncology 2012 7, e1-e2DOI: (10.1097/JTO.0b013e318257fc1d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 A, Chest CT scan performed 15 days after stopping crizotinib treatment showing flare- up disease with dramatic progression of left lung tumor (arrow); (B), Abdominal CT scan showing flare-up disease with the appearance of three liver metastasis (arrows). CT scan performed on June 14, 2011, 15 days after stopping crizotinib treatment. CT, computed tomography. Journal of Thoracic Oncology 2012 7, e1-e2DOI: (10.1097/JTO.0b013e318257fc1d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions